---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-003646"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-19T23:59:59.972403+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bioxytran receives CDSCO approval for first-in-human ProLectin-I trial

## Summary
- India's CDSCO granted IND authorization (CT-06, No. CT/ND/03/2023) to evaluate ProLectin-I injection.
- Trial will assess safety, tolerability, PK/PD; results to guide Phase II in Long COVID and IPF.
- Separate approval from prior ProLectin-M authorization (Dec 2, 2022).
- ProLectin-I targets viral persistence and fibrosis; Long COVID affects 65-100 million worldwide.
- Trial at each site requires ethics committee approval before initiation.

## SEC filing metadata
- accession: 0001493152-23-003646
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315223003646/0001493152-23-003646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315223003646/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-003646
- JSON: https://secwatch.observer/filing/0001493152-23-003646.json
- Plain text: https://secwatch.observer/filing/0001493152-23-003646.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.